OBJECTIVE: In the Human Immunodeficiency Virus (HIV) Network for Prevention Trials (HIVNET) 012 trial in Uganda, 6-8 weeks after single-dose nevirapine (SD-NVP), NVP resistance mutations were detected at a higher rate in women with HIV-1 subtype D than in women with subtype A. Here, we evaluate the rate of NVP resistance mutations in women with subtype C. METHODS: NVP resistance mutations were detected using the ViroSeq HIV-1 Genotyping System. RESULTS: The portion of women with any NVP resistance mutation was higher in those with subtype C (45/65 [69.2%] in the NVP and zidovudine trial, Malawi) than in those in the HIVNET 012 trial with either subtype A (28/144 [19.4%]; P<.0001) or subtype D (35/97 [36.1%]; P<.0001). In a multivariate model, subtype (C vs. A: odds ratio [OR], 8.73 [95% confidence interval {CI}, 4.29-17.76]; C vs. D: OR, 3.38 [95% CI, 1.65-6.93]) and viral load at delivery (OR, 2.35 [95% CI, 1.62-3.40]) independently predicted NVP resistance mutations, but maternal age, parity, and time between SD-NVP and the 6-8-week visit did not. CONCLUSIONS: The rate of NVP resistance mutations after SD-NVP was significantly higher in women with HIV-1 subtype C than in women with subtype A or D. Studies are needed to assess the clinical significance of this finding.
OBJECTIVE: In the Human Immunodeficiency Virus (HIV) Network for Prevention Trials (HIVNET) 012 trial in Uganda, 6-8 weeks after single-dose nevirapine (SD-NVP), NVP resistance mutations were detected at a higher rate in women with HIV-1 subtype D than in women with subtype A. Here, we evaluate the rate of NVP resistance mutations in women with subtype C. METHODS: NVP resistance mutations were detected using the ViroSeq HIV-1 Genotyping System. RESULTS: The portion of women with any NVP resistance mutation was higher in those with subtype C (45/65 [69.2%] in the NVP and zidovudine trial, Malawi) than in those in the HIVNET 012 trial with either subtype A (28/144 [19.4%]; P<.0001) or subtype D (35/97 [36.1%]; P<.0001). In a multivariate model, subtype (C vs. A: odds ratio [OR], 8.73 [95% confidence interval {CI}, 4.29-17.76]; C vs. D: OR, 3.38 [95% CI, 1.65-6.93]) and viral load at delivery (OR, 2.35 [95% CI, 1.62-3.40]) independently predicted NVP resistance mutations, but maternal age, parity, and time between SD-NVP and the 6-8-week visit did not. CONCLUSIONS: The rate of NVP resistance mutations after SD-NVP was significantly higher in women with HIV-1 subtype C than in women with subtype A or D. Studies are needed to assess the clinical significance of this finding.
Authors: Russell B Van Dyke; Nicole Ngo-Giang-Huong; David E Shapiro; Lisa Frenkel; Paula Britto; Anuvat Roongpisuthipong; Ingrid A Beck; Praparb Yuthavisuthi; Sinart Prommas; Thanyawee Puthanakit; Jullapong Achalapong; Nantasak Chotivanich; Wirawan Rasri; Tim R Cressey; Robert Maupin; Mark Mirochnick; Gonzague Jourdain Journal: Clin Infect Dis Date: 2011-12-05 Impact factor: 9.079
Authors: Vlad Novitsky; Melissa Zahralban-Steele; Mary Fran McLane; Sikhulile Moyo; Erik van Widenfelt; Simani Gaseitsiwe; Joseph Makhema; M Essex Journal: J Clin Microbiol Date: 2015-06-03 Impact factor: 5.948
Authors: Sudeb C Dalai; Tulio de Oliveira; Gordon W Harkins; Seble G Kassaye; Jennifer Lint; Justen Manasa; Elizabeth Johnston; David Katzenstein Journal: AIDS Date: 2009-11-27 Impact factor: 4.177
Authors: Sarah E Hudelson; Michelle S McConnell; Danstan Bagenda; Estelle Piwowar-Manning; Teresa L Parsons; Monica L Nolan; Paul M Bakaki; Michael C Thigpen; Michael Mubiru; Mary Glenn Fowler; Susan H Eshleman Journal: AIDS Date: 2010-02-20 Impact factor: 4.177
Authors: James A McIntyre; Mark Hopley; Daya Moodley; Marie Eklund; Glenda E Gray; David B Hall; Patrick Robinson; Douglas Mayers; Neil A Martinson Journal: PLoS Med Date: 2009-10-27 Impact factor: 11.069